Most semaglutide side effects are digestive and temporary. In trials of Wegovy (semaglutide 2.4 mg, FDA-approved), nausea affected 43.9% of participants, diarrhea 29.7%, vomiting 24.5%, and constipation 24.2%. Nearly all events were mild to moderate and peaked during dose escalation. Rarer but serious risks, including pancreatitis and a thyroid boxed warning, require awareness before starting.
Common side effects at a glance
The large majority of semaglutide side effects involve the digestive system. The table below summarizes rates from the STEP clinical trial program for Wegovy (semaglutide 2.4 mg), the FDA-approved weight-management form of semaglutide. Compounded semaglutide is not FDA-approved and has not been evaluated in equivalent clinical trials; these figures describe the approved medication only.
| Side effect | Semaglutide 2.4 mg (Wegovy) | Placebo |
|---|---|---|
| Nausea | 43.9% | 16.1% |
| Diarrhea | 29.7% | 15.9% |
| Vomiting | 24.5% | 6.3% |
| Constipation | 24.2% | 11.1% |
| Any GI event | 72.9% | 47.1% |
Source: Wharton et al., Diabetes, Obesity and Metabolism, 2022, which pooled GI tolerability data across the STEP program. Of all GI events recorded, 98.1% were mild to moderate in severity and 99.5% were classified as non-serious. Only 4.3% of semaglutide-treated participants permanently stopped treatment because of GI side effects, meaning the vast majority were able to continue.
Nausea: the most reported effect
Nausea is the single most frequently reported side effect of semaglutide treatment. In the STEP 1 trial of Wegovy, 43.9% of participants experienced nausea versus 16.1% in the placebo group, per Wilding et al. in the New England Journal of Medicine (2021). The median duration of each nausea episode was just 8 days in the pooled STEP analysis, suggesting that episodes tend to be brief rather than continuous.
The feeling is often described as similar to motion sickness: a low-grade queasiness that tends to be worst in the morning or shortly after eating. It typically peaks around the time of a dose increase and fades over the following one to two weeks as the body adapts to the new level.
Most people find nausea lessens significantly once they reach a stable maintenance dose, usually around week 16 to 20 of treatment. Practical steps that can reduce nausea include eating smaller portions, chewing slowly, and pausing before the feeling of fullness sets in. Details on which foods tend to worsen nausea and which support tolerance are covered in What should you eat while taking semaglutide?
If nausea is disrupting sleep or daily activities, a provider can discuss whether a short course of prescription anti-nausea medication is appropriate.
Constipation and diarrhea
Semaglutide can cause both constipation and diarrhea, and some people experience one and then the other at different points during titration. In the STEP trials of Wegovy, constipation occurred in 24.2% of participants (vs. 11.1% on placebo) and diarrhea in 29.7% (vs. 15.9%), per Wharton et al. (2022).
Of the common GI effects, constipation tends to last longest. The median duration of constipation episodes was 47 days in the pooled analysis, compared to a median of just 3 days for diarrhea. This difference matters: constipation benefits from proactive steps rather than waiting it out.
Strategies that may help with constipation include increasing daily water intake, adding fiber from vegetables, legumes, and whole grains, and taking short walks after meals. For diarrhea, staying well hydrated and temporarily reducing high-fat foods are common first steps. Reducing the overall food volume at each meal also reduces the burden on a digestive system that is already moving more slowly than usual.
Vomiting and heartburn
Vomiting occurred in 24.5% of participants taking Wegovy in the STEP 1 trial, compared with 6.3% on placebo, per Wilding et al. (2021, NEJM). Like nausea, individual vomiting episodes were brief: a median of just 2 days per episode in the pooled STEP analysis.
Heartburn and acid reflux are also reported, though less frequently. GLP-1 receptor agonists slow the rate at which the stomach empties into the small intestine. This gastric emptying delay produces the prolonged feeling of fullness these medications are known for, but it also means stomach acid has more time to contact the lower esophagus, particularly when lying flat after a meal or eating too quickly.
Steps that tend to reduce vomiting and heartburn include eating slowly, stopping before the sense of fullness becomes uncomfortable, waiting at least an hour before lying down after meals, and limiting carbonated drinks on an empty stomach. For a week-by-week look at what digestive symptoms to expect during the first three months, see What should you expect in your first 90 days on a GLP-1?
When side effects are most intense and why they usually fade
GI side effects follow a predictable timing pattern. They are most likely to appear or worsen in the days immediately after a dose increase. Because semaglutide is titrated upward in steps over 16 to 20 weeks, each escalation can bring a brief return of nausea or digestive upset. In the STEP program, GI adverse events peaked in cumulative incidence around week 20 and then plateaued or declined as participants reached and stayed at their target dose.
This pattern shows that the body does adapt. The digestive system becomes less reactive to semaglutide over time, and for most people the side effect burden diminishes substantially after the first few months of treatment.
When symptoms at a given dose are hard to manage, a prescribing provider can consider slowing the escalation schedule. A 2026 analysis published in Frontiers in Endocrinology found that extending the titration period was associated with fewer adverse events and better treatment adherence, supporting a more flexible approach for people who struggle at standard escalation speed. Dose-escalation decisions should always be made with the prescribing clinician rather than adjusted independently.
Serious but rare risks: pancreatitis and gallbladder disease
Beyond common GI effects, the Wegovy prescribing label flags several warnings that are infrequent but important to recognize before starting treatment.
Acute pancreatitis: Across the STEP clinical development program, the rate of adjudication-confirmed acute pancreatitis was approximately 0.2% with semaglutide 2.4 mg, compared with less than 0.1% with placebo. Warning signs include severe upper abdominal or back pain, pain that worsens after eating, and nausea that does not settle. These symptoms require same-day contact with a provider. The Wegovy prescribing label instructs that semaglutide should be discontinued if pancreatitis is confirmed and not restarted.
Gallbladder disease: Gallbladder problems occur more often. In a real-world comparative analysis of GLP-1 users, gallbladder-related adverse events occurred in 2.6% of semaglutide-treated patients versus 1.2% in the comparator group, with gallstones specifically reported in 1.6% versus 0.7%, per Diabetology and Metabolic Syndrome 2024 (PMC11616335). This elevated risk appeared even after accounting for the degree of weight loss, suggesting a direct drug effect beyond what weight change alone would explain. Symptoms of gallbladder problems include pain in the upper right abdomen (particularly after fatty meals), fever, or yellowing of the skin or eyes. Any of these warrants prompt medical evaluation.
The thyroid C-cell boxed warning: what it means
The most prominent warning on the Wegovy label is a boxed warning about thyroid C-cell tumors. In animal studies, semaglutide caused thyroid C-cell tumors at clinically relevant exposures. The FDA's current prescribing information states that the human relevance of these findings has not been determined; there are no long-term human studies establishing that semaglutide causes medullary thyroid carcinoma (MTC) in people.
Despite this uncertainty, the label includes an absolute contraindication for anyone with a personal or family history of MTC, or for anyone with Multiple Endocrine Neoplasia syndrome type 2 (MEN2), a rare inherited condition that substantially raises MTC risk. These individuals should not take semaglutide.
For people without these risk factors, the current human evidence does not establish a thyroid cancer risk. Still, providers ask about personal and family thyroid history as a routine part of the prescribing evaluation. If a lump appears in the neck, or if there is unexplained hoarseness or difficulty swallowing while on treatment, a provider should be contacted promptly.
Hypoglycemia: who is actually at risk
Semaglutide stimulates insulin release in a glucose-dependent manner, meaning it prompts insulin secretion primarily when blood sugar is elevated. This built-in mechanism makes low blood sugar (hypoglycemia) unlikely in people who do not also use insulin or sulfonylurea medications.
In the SELECT cardiovascular outcomes trial, which enrolled 17,604 adults with overweight or obesity but without diabetes, hypoglycemia was not identified as a meaningful safety concern for participants who were not on insulin. This is reassuring for people taking semaglutide for weight management without a diabetes diagnosis.
The risk picture changes for people using insulin or a sulfonylurea alongside semaglutide. When those medications are present, hypoglycemic episodes are possible, and providers typically adjust insulin or sulfonylurea doses before or after starting semaglutide in people with type 2 diabetes. Blood glucose monitoring guidance should come directly from the prescribing provider for anyone in this group.
Who should not take semaglutide
Semaglutide has a clear set of contraindications. The FDA-approved Wegovy prescribing information lists three absolute contraindications:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- Known hypersensitivity to semaglutide or any excipient in the formulation
Beyond these, semaglutide should be discontinued at least two months before a planned pregnancy, based on developmental risk signals seen in animal studies. The medication is not appropriate during pregnancy. A history of pancreatitis warrants a careful provider discussion before starting, as does severe kidney or liver impairment.
People considering compounded semaglutide should know that compounded semaglutide is not FDA-approved and has not been studied in the trials that established the side effect profile described in this article. For a detailed look at what is and is not known about compounded formulations, see Is compounded semaglutide safe?
Protecting lean body mass is also worth planning for before starting. Rapid weight loss can reduce muscle as well as fat. How do you prevent muscle loss on a GLP-1? covers protein targets and resistance training strategies that support muscle preservation during treatment.
When to contact your provider
Most semaglutide side effects are manageable at home, but several symptoms require prompt contact with a healthcare provider:
- Severe or persistent abdominal pain, especially pain radiating to the back that does not improve (possible pancreatitis)
- Upper right abdominal pain, fever, or jaundice (yellowing of skin or eyes), which may indicate a gallbladder problem
- Signs of a serious allergic reaction: difficulty breathing, swelling of the face, lips, or throat, or a severe rash
- A lump or swelling in the neck, hoarseness, or difficulty swallowing (symptoms that should prompt thyroid evaluation)
- Symptoms of low blood sugar in people who also take insulin or sulfonylureas: shakiness, sweating, rapid heartbeat, or confusion
- Vision changes in people with a history of diabetic retinopathy, as rapid blood sugar improvement can temporarily affect the eyes
Anyone experiencing side effects severe enough to prevent eating, drinking, or normal daily activities should contact their prescribing provider rather than stopping medication on their own. Dose adjustments, temporary treatment holds, or supportive medications can often resolve the issue without abandoning treatment. Starting, stopping, or changing a medication dose should always involve a licensed clinician.